Effect of High-calcium Intake on Substrate Metabolism During Exercise

September 4, 2013 updated by: Javier Gonzalez, Northumbria University

The Impact of a Calcium Supplementation on Lipid Metabolism During Exercise.

A high-calcium intake can accelerate fat loss under energy-restricted diets. Part of this may be due to a shift in substrate metabolism where there is an increase in the rate of fat oxidation. However, whether high-calcium intake can influence substrate metabolism during exercise is not known. Accordingly, we aim to investigate the effect of 2 weeks of high-calcium intake on substrate metabolism during exercise.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

13

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Tyne and Wear
      • Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 8ST
        • Northumbria University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Physically active (moderate-vigorous exercise >3 time per week)
  • Male
  • 18-40 yrs of age

Exclusion Criteria:

  • Smoker
  • Known Food Allergies
  • Metabolic disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control
A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
Dietary supplement: Placebo
Experimental: High-Calcium
A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
Dietary supplement: Calcium
Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Substrate metabolism
Time Frame: 60 s samples every 3 min for 15 min
Substrate metabolism will be assessed by the respiratory exchange ratio (rate of carbon dioxide production/rate of oxygen consumption) from samples of expired gas collected during the first 15 minutes of an incremental cycling test.
60 s samples every 3 min for 15 min

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma non-esterified fatty acid concentrations
Time Frame: Every 3 min for 15 min
Non-esterified fatty acid concentrations will be determined from plasma samples collected during the first 15 minutes of an incremental cycling test to indicate fatty acid availability.
Every 3 min for 15 min
Plasma glycerol concentrations
Time Frame: Every 3 min for 15 min
Glycerol concentrations will be determined from plasma samples collected during the first 15 minutes of an incremental cycling test as a marker of lipolysis.
Every 3 min for 15 min

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum parathyroid hormone concentration
Time Frame: Baseline (Pre-post 2 week supplementation)
Parathyroid hormone concentrations will be determined at rest before and after supplementation periods as a indicator of calcium status.
Baseline (Pre-post 2 week supplementation)
Plasma glucose-dependent insulinotropic peptide concentration
Time Frame: Baseline (Pre-post 2 week supplementation)
Glucose-dependent insulinotropic peptide concentrations will be determined at rest before and after supplementation periods as a potential mechanism of any changes in metabolism.
Baseline (Pre-post 2 week supplementation)
Plasma glucagon-like peptide-1 concentration
Time Frame: Baseline (Pre-post 2 week supplementation)
Glucagon-like peptide-1 concentrations will be determined at rest before and after supplementation periods as a potential mechanism of any changes in metabolism.
Baseline (Pre-post 2 week supplementation)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Northumbria University

Investigators

  • Principal Investigator: Emma J Stevenson, PhD, Northumbria University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

January 28, 2013

First Submitted That Met QC Criteria

January 29, 2013

First Posted (Estimate)

January 30, 2013

Study Record Updates

Last Update Posted (Estimate)

September 6, 2013

Last Update Submitted That Met QC Criteria

September 4, 2013

Last Verified

September 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 32AN3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lipid Metabolism

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe